Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats

Gráses, F.; Perelló, Joan; Prieto, Rafel M.; Simonet, B.M.; Torres, José

doi:10.1016/j.lfs.2003.11.030

Cited by 47 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…48,49 Phytate levels found in tissues reflect dietary intake, 34,35 as well as topical absorption. 36 Bisphosphonates are commonly used for treating osteoporosis, and have also been shown to act as crystallization inhibitors both in vitro and in vivo.…”

Section: Discussionmentioning

confidence: 99%

Effect of Crystallization Inhibitors on Vascular Calcifications Induced by Vitamin D A Pilot Study in Sprague-Dawley Rats

Gráses

Sanchís

Perelló

et al. 2007

Circ J

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Effect of Crystallization Inhibitors on Vascular Calcifications Induced by Vitamin D A Pilot Study in Sprague-Dawley Rats

Gráses

Sanchís

Perelló

et al. 2007

Circ J

View full text Add to dashboard Cite

“…As regards to biomineralization, different in vitro and in vivo studies have demonstrated that IP6 is a potent inhibitor of crystallization of calcium salts (oxalate and phosphate salts) [15]–[18]. It has been demonstrated that IP6 inhibits pericardial [19], vascular [20], tooth enamel [21] and renal calcification [22], [23], in addition to inhibiting dental tartar formation [24].…”

Section: Introductionmentioning

confidence: 99%

Inositol Hexakisphosphate Inhibits Osteoclastogenesis on RAW 264.7 Cells and Human Primary Osteoclasts

et al. 2012

View full text Add to dashboard Cite

BackgroundInoxitol hexakisphosphate (IP6) has been found to have an important role in biomineralization and a direct effect inhibiting mineralization of osteoblasts in vitro without impairing extracellular matrix production and expression of alkaline phosphatase. IP6 has been proposed to exhibit similar effects to those of bisphosphonates on bone resorption, however, its direct effect on osteoclasts (OCL) is presently unknown.Methodology/Principal FindingsThe aim of the present study was to investigate the effect of IP6 on the RAW 264.7 monocyte/macrophage mouse cell line and on human primary osteoclasts. On one hand, we show that IP6 decreases the osteoclastogenesis in RAW 264.7 cells induced by RANKL, without affecting cell proliferation or cell viability. The number of TRAP positive cells and mRNA levels of osteoclast markers such as TRAP, calcitonin receptor, cathepsin K and MMP-9 was decreased by IP6 on RANKL-treated cells. On the contrary, when giving IP6 to mature osteoclasts after RANKL treatment, a significant increase of bone resorption activity and TRAP mRNA levels was found. On the other hand, we show that 1 µM of IP6 inhibits osteoclastogenesis of human peripheral blood mononuclear cells (PBMNC) and their resorption activity both, when given to undifferentiated and to mature osteoclasts.Conclusions/SignificanceOur results demonstrate that IP6 inhibits osteoclastogenesis on human PBMNC and on the RAW264.7 cell line. Thus, IP6 may represent a novel type of selective inhibitor of osteoclasts and prove useful for the treatment of osteoporosis.

show abstract

“…Moreover, from the 1980s to the present, important physiological functions of InsP 6 have been suggested as its properties as an antioxidant 17,18) and its role in colon cancer prevention. 19,20) The InsP 6 present in urine and biological fluids also exhibited an important role in preventing pathological calcifications as renal calculi [21][22][23] or calcinosis cutis, 24) due to its powerful capacity to act as crystallization inhibitor of calcium salts.Finally, the most recent observations about the properties of InsP 6 are related to its dermatological use. The majority of those applications are referred to their important action on premature aging or as discolouring agent of the skin.…”

mentioning

confidence: 99%

Study of the Absorption of Myo-Inositol Hexakisphosphate (InsP6) through the Skin

Gráses

Perelló

Isern

et al. 2005

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

Myo-inositol hexakisphosphate (InsP 6 ) is an abundant component of plant seeds. In whole grain cereals it ranges from 1.5 to 6.4% and it is mostly associated with calcium and magnesium ions, the so-called phytin. 1,2) Recently it was found that InsP 6 is also present in all mammalian organs, tissues and fluids but at significantly low amounts. Moreover, it was demonstrated that the levels found in biological fluids (blood, urine, interstitial liquid) and mammalian tissues clearly depended on the dietary intake. [3][4][5] Diverse studies performed by Mellanby demonstrated that a high InsP 6 content in some diets, as sodium salt, reduced calcium absorption and induced rickets. 6) Ever since up to now, several studies have attributed "anti-nutritional" properties to phytate. [7][8][9][10][11] Nevertheless, other studies [12][13][14][15][16] have shown that those findings are not quite so clear and simple as mentioned. Moreover, from the 1980s to the present, important physiological functions of InsP 6 have been suggested as its properties as an antioxidant 17,18) and its role in colon cancer prevention. 19,20) The InsP 6 present in urine and biological fluids also exhibited an important role in preventing pathological calcifications as renal calculi [21][22][23] or calcinosis cutis, 24) due to its powerful capacity to act as crystallization inhibitor of calcium salts.Finally, the most recent observations about the properties of InsP 6 are related to its dermatological use. The majority of those applications are referred to their important action on premature aging or as discolouring agent of the skin.25) Also some studies seem to demonstrate a capacity of InsP 6 to inhibit skin cancer. 26,27) In the present paper a first study of the absorption of InsP 6 through the skin is developed. MATERIALS AND METHODS Animals, Diets and Experimental DesignTwenty-four female Wistar rats of approximately 225 g from Harlan Iberica s.l. (Barcelona, Spain) were acclimated in the course of 7 d to our animal house. Animals were kept in Plexiglas cages (two animals per cage) at a temperature of 21Ϯ1°C and relative humidity of 60Ϯ5% with a 12-h on-off light cycle. After this period, animals were randomly assigned into four groups of six rats respectivelly. Rats were fed with 4068.02 Reference Diet (HopeFarms BV, Woerden, The Netherlands), a synthetic purified diet (Table 1) in which InsP 6 is undetectable.After a period of 16 d consuming such diet, during which the urinary InsP 6 became undetectable, rats were topically treated once a day with 4 g of a standard cream with a supplement of 0.4, 1.2 and 2.0% of InsP 6 as sodium salt or 2.0% of InsP 6 as calcium magnesium salt (phytin). The surface of treatment was about 50 cm 2 . The application area was located on the back skin of the animal and was previously shaved using an electric shaver (each 4 d). During cream treatment animals were located individually to avoid licking cream. pH of all creams was adjusted to 4-4.5 (see Table 2). Samples of 24-h urine were collected at days 0, 7 ...

show abstract

Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats

Cited by 47 publications

References 31 publications

Effect of Crystallization Inhibitors on Vascular Calcifications Induced by Vitamin D A Pilot Study in Sprague-Dawley Rats

Effect of Crystallization Inhibitors on Vascular Calcifications Induced by Vitamin D A Pilot Study in Sprague-Dawley Rats

Inositol Hexakisphosphate Inhibits Osteoclastogenesis on RAW 264.7 Cells and Human Primary Osteoclasts

Study of the Absorption of Myo-Inositol Hexakisphosphate (InsP6) through the Skin

Contact Info

Product

Resources

About